CARsgen Announced 2024 Annual Results

CARsgen’s Claudin18.2 CAR-T Therapy Satri-cel Granted Breakthrough Therapy Designation by the NMPA

CARsgen’s Allogeneic CD19/CD20 CAR-T Therapy Administers First Dose in a Patient with Autoimmune Disease

CARsgen Therapeutics Introduced Zhuhai SB Xinchuang to Accelerate Allogeneic CAR-T Cell Products Development in Mainland China

CARsgen’s First Enrolled Subject in the THANK-u Plus™ Platform-Based Allogeneic CAR-T Trial Achieves sCR at Week 4

CARsgen’s Allogeneic CD38 CAR-T Therapy Administers First Dose in an Investigator-Initiated Trial

CARsgen’s Allogeneic CD19/CD20 CAR-T Therapy Administers First Dose in an Investigator-Initiated Trial

CARsgen Announces the Initiation of an Investigator-Initiated Trial for an Allogeneic CD19/CD20 CAR-T Therapy

CARsgen Announces Positive Topline Results from China GC/GEJ Pivotal Phase II Clinical Trial of Claudin18.2 CAR-T (Satri-cel)

CARsgen’s Allogeneic CAR-T Product Developed on the THANK-u Plus Platform Administers First Dose in an IIT